2840 Brody, Jonathan - Thomas Jefferson University - Thomas Jefferson University

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Room 623
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. Upgrading gemcitabine with recycled kinase inhibitors
  2. Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types
  3. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells
  4. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
  5. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial
  6. Structural implications for selective targeting of PARPs
  7. Targeting cell cycle and hormone receptor pathways in cancer
  8. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
  9. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer
  10. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer
  11. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
  12. Dual roles of PARP-1 promote cancer growth and progression
  13. Pancreatic cancer and premalignant tumors: Molecular aspects
  14. Molecular-based and alternative therapies for pancreatic cancer: Looking "out of the box"
  15. HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells
  16. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
  17. A novel survival-based tissue microarray of pancreatic cancer validates muc1 and mesothelin as biomarkers
  18. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient
  19. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized
  20. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?